Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21129
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMarti-Carvajal, A.en
dc.contributor.authorSalanti, G.en
dc.contributor.authorCardona, A. F.en
dc.date.accessioned2015-11-24T19:12:53Z-
dc.date.available2015-11-24T19:12:53Z-
dc.identifier.issn1469-493X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21129-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAge Factorsen
dc.subjectChilden
dc.subjectHospital Mortalityen
dc.subjectHumansen
dc.subjectProtein C/*therapeutic useen
dc.subjectRandomized Controlled Trials as Topicen
dc.subjectRecombinant Proteins/therapeutic useen
dc.subjectSepsis/*drug therapy/mortalityen
dc.subjectShock, Septic/drug therapy/mortalityen
dc.titleHuman recombinant activated protein C for severe sepsisen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1002/14651858.CD004388.pub3-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/18254048-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004388.pub3/abstract-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2008-
heal.abstractBACKGROUND: Sepsis is a common, expensive and frequently fatal condition. There is an urgent need for developing new therapies to further reduce severe sepsis-induced mortality. One of those approaches is the use of human recombinant activated protein C (APC). OBJECTIVES: We assessed the clinical effectiveness of APC for the treatment of patients with severe sepsis or septic shock. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2005, Issue 2); MEDLINE (1966 to 2005); EMBASE (1980 to 2005) and LILACS (1982 to 2005). We contacted researchers and organizations working in the field. We did not have any language restriction. SELECTION CRITERIA: We included randomized controlled trials (RCTs) assessing the effects of APC for severe sepsis in adults and children. We excluded studies on neonates. DATA COLLECTION AND ANALYSIS: We independently performed study selection, quality assessment and data extraction. We estimated relative risks (RR) for dichotomous outcomes. We measured statistical heterogeneity using I-squared (I(2)). We used a random-effects model. MAIN RESULTS: We included four studies involving 4911 participants (4434 adults and 477 paediatric patients). For 28-day mortality, APC did not reduce the risk of death in adult participants with severe sepsis (pooled RR 0.92, 95% confidence interval (CI) 0.72 to 1.18; P = 0.50, I(2) = 72%). The effectiveness of APC did not seem to be associated with the degree of severity of sepsis (two studies): for an APACHE II score less than 25 the RR was 1.04 (95% CI 0.89 to 1.21; P = 0.70), and in participants with an APACHE II score of 25 or more the RR was 0.90 (95% CI 0.54 to 1.49; P = 0.68). APC use was, however, associated with a higher risk of bleeding (RR 1.48 (95% CI 1.07 to 2.06; P = 0.02, I(2) = 8%). Two studies were stopped early because there was little chance of reaching the efficacy endpoint by completion of the trial. AUTHORS' CONCLUSIONS: This updated review found no evidence suggesting that APC should be used for treating patients with severe sepsis or septic shock. Additionally, APC seems to be associated with a higher risk of bleeding. Unless additional RCTs provide evidence of a treatment effect, policy-makers, clinicians and academics should not promote the use of APC.en
heal.journalNameCochrane Database Syst Reven
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons